ODAC Chairs Reveal Challenges, High Drama in a Decade of Service

    May 2013 in “ Oncology Times
    Peggy Eastman
    Studysummary This narrative review reflects on the challenges faced by FDA's Oncologic Drugs Advisory Committee members, highlighting public pressure, decision-making complexity, and the evolving landscape of cancer drug development.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →